# Celmatix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celmatix

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.celmatix.com
- Total disclosed funding: $2.3M
- Latest round: Series A (Mar 1, 2012)
- Investors on record: 1

## About

Celmatix Inc is a biotechnology company focused on women's health, developing innovative therapeutics for conditions such as ovarian dysfunction. Their research emphasizes improving fertility outcomes and addressing painful health issues.Founded in 2010 and headquartered in New York, US, Celmatix Inc specializes in therapeutics for women's health, particularly targeting ovarian dysfunction. The company was founded by Piraye Beim, who has a history in the biotech sector. Celmatix has secured a total of USD 3.76 mn in funding, with the latest round occurring on September 15, 2015. The firm has engaged in three notable funding deals.Celmatix Inc. specializes in innovative therapeutics focused on women's health, particularly in addressing conditions related to ovarian dysfunction. The company’s primary offerings include drug programs targeting endometriosis, polycystic ovary syndrome (PCOS), and ovarian aging. Their pipeline features a novel AMH receptor agonist, which aims to improve ovarian health, as well as an oral FSH receptor agonist designed to enhance fertility treatment outcomes. Additionally, Celmatix has developed an immunotherapy for endometriosis and is working on a Jun-N-terminal kinase (JNK) inhibitor to address pain and inflammation associated with various women's health indications. These products are primarily aimed at healthcare providers and patients in the United States and Brazil, reflecting the company’s focus on geographies with significant unmet needs in women's health.Celmatix operates on a revenue model that leverages partnerships and grants, particularly with governmental agencies such as the Advanced Research Projects Agency for Health (ARPA-H). The company has received substantial funding, including a USD 3.5 mn award to support its ovarian aging program. Revenue generation is expected to occur through collaborations with pharmaceutical companies, healthcare providers, and potentially through direct sales of therapeutics once they reach market approval. The company’s drug programs indicate a focus on B2B transactions with healthcare institutions and direct-to-consumer models once products are commercially available. Pricing details for specific products or services have not been disclosed, but the strategic focus is on developing groundbreaking solutions that address critical health issues faced by women.Celmatix is actively working on several new products, including a novel AMH receptor agonist and an oral FSH receptor agonist aimed at improving fertility treatment outcomes. The company is also looking to expand its presence in Brazil and other geographical regions with unmet needs in women's health within the next few years. The recent funding of USD 3.76 mn will support these initiatives, allowing for further development of their drug programs and potential market introductions.

## Funding rounds

- Series A, Mar 1, 2012, $1.5M — Topspin Partners
- Series A, Feb 25, 2011, $0.8M — Topspin Partners

## Investors

- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series A